Effects of prolonged use of azithromycin in patients with cystic fibrosis: A meta-analysis

Pulmonary Pharmacology and Therapeutics

Volumn 22, Issue 6, 2009, Pages 467-472

  Florescu, D F ^a   Murphy, P J ^a   Kalil, A C ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Azithromycin; Cystic fibrosis; FEV1; FVC; Pseudomonas

Indexed keywords

AZITHROMYCIN; PLACEBO;

ARTICLE; BACTERIAL COLONIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG FIBROSIS; LUNG FUNCTION TEST; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; PSEUDOMONAS; RANDOMIZED CONTROLLED TRIAL; SPUTUM ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BIOLOGICAL MARKERS; CHILD; CYSTIC FIBROSIS; FEMALE; HUMANS; INFLAMMATION; MALE; PUBLICATION BIAS; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME; VITAL CAPACITY; YOUNG ADULT;

EID: 71249138160     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2009.03.002     Document Type: Article

References (34)

1. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2006; 2007.
2. Davis P.B., Drumm M., and Konstan M.W. Cystic fibrosis. Am J Respir Crit Care Med 154 (1996) 1229-1256
3. Ramsey B.W. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 335 (1996) 179-188
4. Boucher R.C. Human airway ion transport. Part one. Am J Respir Crit Care Med 150 (1994) 271-281
5. Boucher R.C. Human airway ion transport. Part two. Am J Respir Crit Care Med 150 (1994) 581-593
6. Main E., Prasad A., and Schans C. Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis. Cochrane Database Syst Rev (2005) (1):CD002011
7. Fuchs H.J., Borowitz D.S., Christiansen D.H., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 331 (1994) 637-642
8. Ramsey B.W., Burns J., and Smith A. Safety and efficacy of tobramycin-solution for inhalation in patients with cystic fibrosis: the results of two fase III placebo controlled clinical trials. Pediatr Pulmonol Suppl 14 (1997) 137-138
9. Donaldson S.H., Bennett W.D., Zeman K.L., et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 354 (2006) 241-250
10. Saiman L., Marshall B.C., Mayer-Hamblett N., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290 (2003) 1749-1756
11. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
12. Sterne J.A., Gavaghan D., and Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53 (2000) 1119-1129
13. Southern K.W., Barker P.M., and Solis A. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev (2004) (2):CD002203
14. Clement A., Tamalet A., Leroux E., et al. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 61 (2006) 895-902
15. Equi A., Balfour-Lynn I.M., Bush A., et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360 (2002) 978-984
16. Wolter J., Seeney S., Bell S., et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 57 (2002) 212-216
17. Molinari G., Guzman C.A., Pesce A., et al. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother 31 (1993) 681-688
18. Nguyen D., Emond M.J., Mayer-Hamblett N., et al. Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatr Pulmonol 42 (2007) 533-541
19. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 125 (2004) 41S-451
20. Tsai W.C., Rodriguez M.L., Young K.S., et al. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med 170 (2004) 1331-1339
21. Legssyer R., Huaux F., Lebacq J., et al. Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. Respir Res 7 (2006) 134
22. Yamasawa H., Oshikawa K., Ohno S., et al. Macrolides inhibit epithelial cell-mediated neutrophil survival by modulating granulocyte macrophage colony-stimulating factor release. Am J Respir Cell Mol Biol 30 (2004) 569-575
23. Saiman L., Mayer-Hamblett N., Campbell P., et al. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 172 (2005) 1008-1012
24. Nagino K., and Kobayashi H. Influence of macrolides on mucoid alginate biosynthetic enzyme from Pseudomonas aeruginosa. Clin Microbiol Infect 3 (1997) 432-439
25. Nalca Y., Jansch L., Bredenbruch F., et al. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob Agents Chemother 50 (2006) 1680-1688
26. Tateda K., Ishii Y., Hirakata Y., et al. Profiles of outer membrane proteins and lipopolysaccharide of Pseudomonas aeruginosa grown in the presence of sub-MICs of macrolide antibiotics and their relation to enhanced serum sensitivity. J Antimicrob Chemother 34 (1994) 931-942
27. Tateda K., Ishii Y., Matsumoto T., et al. Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob Agents Chemother 40 (1996) 2271-2275
28. Wagner T., Soong G., Sokol S., et al. Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients. Chest 128 (2005) 912-919
29. Imamura Y., Higashiyama Y., Tomono K., et al. Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane. Antimicrob Agents Chemother 49 (2005) 1377-1380
30. Mizukane R., Hirakata Y., Kaku M., et al. Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob Agents Chemother 38 (1994) 528-533
31. Baumann U., King M., App E.M., et al. Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties. Can Respir J 11 (2004) 151-155
32. Giamarellos-Bourboulis E.J. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 31 (2008) 12-20
33. Saiman L., Chen Y., Gabriel P.S., et al. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 46 (2002) 1105-1107
34. McCormack J., Bell S., Senini S., et al. Daily versus weekly azithromycin in cystic fibrosis patients. Eur Respir J 30 (2007) 487-495